Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W5SA | ISIN: US9224751084 | Ticker-Symbol: VEE
Tradegate
12.02.26 | 11:22
148,35 Euro
-0,57 % -0,85
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
VEEVA SYSTEMS INC Chart 1 Jahr
5-Tage-Chart
VEEVA SYSTEMS INC 5-Tage-Chart
RealtimeGeldBriefZeit
148,35149,0511:39
148,35149,0511:39
PR Newswire
436 Leser
Artikel bewerten:
(2)

Veeva Systems: Grünenthal Advances Global Regulatory Information Management and Operations with Veeva

Global leader in pain treatments relies on Veeva RIM to simplify regulatory processes, drive standardization, foster collaboration, and accelerate delivery of medicines to patients

BARCELONA, Spain, June 25, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Grünenthal is advancing its global regulatory organization with Veeva RIM. By streamlining regulatory information management (RIM) on a single, cloud-based platform, Grünenthal can respond faster to changing regulations and increase process efficiency, from submission planning to health authority submissions to tracking of approvals and decisions.

Veeva Systems

"With Veeva RIM, Grünenthal is transforming and simplifying its global regulatory processes, improving data oversight and visibility, and enabling greater collaboration across the organization to ultimately bring safe and effective medicines to patients," said Argha Nag, vice president and head of RIM and R&D digital transformation at Grünenthal. "This unified approach will eliminate data silos, improve workflow efficiency, and empower our teams to focus on more strategic activities."

Grünenthal is a leader in pain management focused on addressing unmet medical needs worldwide. With Veeva RIM, the company gains stronger alignment across global regulatory teams, improved data oversight, and the flexibility to scale. By bringing all cross-functional regulatory processes and information together in one application, teams can efficiently respond to regulatory needs and ensure ongoing compliance globally.

"Veeva RIM provides Grünenthal with the unified data and workflow platform they need to gain deeper insights into their regulatory processes," said Paul Attridge, vice president, RIM at Veeva. "This enhanced visibility and control will enable them to make faster, more informed decisions to accelerate the delivery of vital pain treatments to patients."

Veeva RIM is part of Veeva Development Cloud, the technology foundation for product development, bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.

Additional Information
For more on Veeva RIM, visit: veeva.com/eu/VeevaRIM
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo_v2.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/grunenthal-advances-global-regulatory-information-management-and-operations-with-veeva-302489570.html

© 2025 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.